Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences

SIMPLE SUMMARY: This paper deals with Belantamab mafodotin, a novel anti-BCMA antibody-drug conjugate licensed by regulatory agencies for the treatment of anti-CD38-refractory multiple myeloma patients. In addition to describing the mechanism of action and general information about the drug, this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Morè, Sonia, Offidani, Massimo, Corvatta, Laura, Petrucci, Maria Teresa, Fazio, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251850/
https://www.ncbi.nlm.nih.gov/pubmed/37296910
http://dx.doi.org/10.3390/cancers15112948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251850/
https://www.ncbi.nlm.nih.gov/pubmed/37296910
http://dx.doi.org/10.3390/cancers15112948

Ejemplares similares